The Medtech Impact Podcast

Join us on this episode as we delve into a "silent epidemic" affecting millions: meniscus root tears, a leading cause of knee arthritis. Our guest, Dr. Chris Anderson, founding surgeon and Chief Medical Officer of Native Orthopedics, reveals the hidden prevalence of this debilitating injury, explaining how it impacts over 800,000 Americans annually and the critical need for a new approach to knee preservation. This episode uncovers why this problem has been historically overlooked and the limitations of traditional repair methods.Discover how Native Orthopedics is revolutionizing soft tissue repair with their FDA breakthrough-designated "Dragonfly" device. Dr. Anderson shares the ingenious, "finger trap" mechanism behind this knotless and adjustable solution, designed by a surgeon for surgeons. Learn how this innovation simplifies complex procedures, improves biomechanical repair, and is poised to introduce a new era of light-touch surgical solutions across sports medicine and beyond, promising better outcomes and faster recovery for patients. A fishing inspired tale that is sure to leave you informed and inspired.

In this episode of the MedTech Impact Podcast, Charles Gellman, CEO and Co-Founder of HiDo Health, discusses the company's mission to eliminate medication errors in the home. Gelman introduces their AI robotic caregiver, a system designed to ensure patients take the right medication at the right time. Unlike existing medication adherence solutions that rely on patient self-reporting or simple reminders, HiDo Health's technology automates the process, knows the medication name, dosage, frequency, and count, and even records consumption. This approach aims to stabilize chronic disease, reduce hospitalizations, and improve the overall quality of care.Charles emphasizes that the device was designed with significant patient input, focusing on accountability and caregiver needs. The system uses existing pill bottles with a special cap containing an RFID chip, and incorporates face ID and video recording to confirm medication intake. This technology integrates data for both patients and providers, and early results show a substantial reduction in hospitalizations and cost savings. HiDo Health is partnering directly with payers to get the device to patients, and is focused on expanding awareness of the technology, so be sure to tune in, so you can be informed and inspired.

This episode features Yashar Seyed Vahedein, CEO and Co-founder of Coredio, a company tackling the significant problem of heart failure management. Yashar outlines the immense global and US prevalence of heart failure, the high rates of readmission due to inadequate post-discharge monitoring, and the substantial financial burden this places on hospitals and payers. He highlights the limitations of current standard care (blood pressure cuffs and scales) in providing timely and accurate cardiac insights, contrasting them with the invasiveness and cost of solutions like catheterization and implantable devices.Coredio's innovative solution is a software platform that leverages existing wearable devices (like smartwatches and blood pressure cuffs) and patented AI and physics-based technology to extract key cardiac metrics comparable to those obtained through invasive procedures. This non-invasive approach aims to improve guideline-directed medication therapy adherence, reduce hospital readmissions and length of stay, and ultimately enhance patient outcomes by providing clinicians with timely data and enabling proactive intervention – all without requiring new devices for patients or hospitals. Tune in to learn more about this exciting startup so you can be informed and inspired.

In this episode, hosts Kyle Kruse and Richard Meiklejohn, interview Joseph ‘Yossi' Mossel, CEO and Co-founder of Ibex Medical Analytics, about the company's innovative use of AI in cancer diagnostics. Yossi discusses the critical problem of diagnostic errors in pathology, which can reach up to 10% in some labs, and the growing shortage of pathologists worldwide. Ibex's AI technology acts as a "digital assistant" to pathologists, pre-analyzing cases and highlighting areas of concern, thereby increasing accuracy and efficiency.Yossi emphasizes that Ibex's AI is designed to augment, not replace, pathologists, allowing them to focus on complex cases while ensuring accuracy in routine diagnoses. The conversation touches on all the incredible data and partner foundations that been developed, which has led to significant deployments in Europe and the United States. Tune in to learn more about how Ibex is re-shaping pathology so you can be informed and inspired.

In this episode, we sit down with Dr. Nicholas Nikolov, Chief Medical Officer of Cellsound Aesthetics, to discuss a revolutionary approach to aesthetic treatments. Dr. Nikolov, a plastic surgeon, shares his journey from traditional invasive procedures to pioneering non-invasive solutions using non-focused ultrasound technology. Cellsound Aesthetics aims to rejuvenate tissue, improve blood flow, and contour the body without causing trauma or downtime. Dr. Nikolov details how the technology, originally developed for wound healing, has evolved to address various aesthetic concerns, offering patients a comfortable and effective alternative to traditional methods.Dr. Nikolov explains the science behind Cellsound, highlighting its unique ability to penetrate deep tissue layers and stimulate cellular activity without causing injury. He emphasizes the importance of patient comfort and the positive impact of the technology on their overall well-being. The conversation also delves into the company's go-to-market strategy, clinical study results, and the comprehensive training and support provided to practitioners. Dr. Nikolov's passion for the technology and its potential to transform the aesthetic industry is evident, making this episode one sure to leave you informed and inspired.

This episode features Prathamesh Prabhudasai, co-founder and CEO of SafeBVM, discussing the critical issue of ineffective manual ventilation during resuscitation. We uncover the alarming statistic that up to 50% of patients experience hypoxia due to improper bag-valve mask (BVM) use. SafeBVM addresses this problem with a novel device that works with any commercially available BVM, providing a flow-limiting valve to ensure safer and more effective breaths. Prath also emphasizes the challenges faced by healthcare providers due to infrequent BVM use and high staff turnover, and how SafeBVM's technology helps maintain competency and improve patient outcomes.SafeBVM's approach offers a comprehensive solution that includes training coupled with their optimized manual bag for ventilation. Prath touches on the importance of federal funding in supporting clinical trials and supporting their development journey. Thanks to this foundation, the company has already seen significant success in cities like Colorado Springs and Saint Charles, with positive clinical outcomes and growing adoption. The company is now focusing on scaling, while also preparing to release exciting clinical trial data, be sure to tune in so you can be informed and inspired.

This episode features Orahn Preiss-Bloom, Chief Innovation Officer of OSSIO, discussing the company's revolutionary tech that promotes natural healing in bones. OSSIO is tackling the long-standing issues associated with metal implants in orthopedic surgery, which often lead to complications like hardware removal surgeries, patient pain, and increased healthcare costs. Orahn explains how their OSSIOfiber product, a composite material made of biocompatible mineral fibers, provides the necessary strength for bone fixation while allowing the body to naturally remodel it into bone over time, eliminating the need for future hardware removal. The conversation delves into the challenges of bringing novel medical technologies to market, the importance of focusing on procedure-specific solutions, and the intricacies of building a successful go-to-market strategy in the orthopedic space. Orahn shines a light on how the market is shifting towards procedure ownership, where companies provide comprehensive solutions rather than just individual tools. Packed with insights into navigating the regulatory landscape, building a strong commercial team, and optimizing distribution strategies, this conversation will definitely leave you informed and inspired.

This episode features Ben Merewitz, CEO and Co-founder of Agile Devices. Ben discusses the challenges faced by interventional radiologists when navigating complex anatomy with traditional microcatheters, such as difficulties in maneuvering through tortuous vessels and achieving precise target placement. Agile Devices has developed a novel, microcatheter with active tip control, called Angler, that overcomes these limitations by allowing real-time control of the tip's shape, enabling physicians to navigate complex anatomy with greater ease and precision.The company has received FDA clearance for the Angler and is currently conducting limited releases to gather further clinical data and demonstrate the device's effectiveness in various interventional procedures, such as embolization. Ben highlights the importance of the Boston area's vibrant medical device ecosystem in the development of this innovative technology and discusses the company's future plans, including expanding into new markets and developing new applications for their deflectable technology platform. With an ‘agile' approach, Ben's story is sure to keep you informed and inspired.

This episode features Andrew Goldsmith, Medical Director of UltraSight, and Ramya Singh, Chief Commercial Officer. They discuss the challenges of limited access to echocardiography due to a shortage of cardiac sonographers and the resulting delays in patient care. UltraSight addresses this by developing AI-powered software that guides clinicians in acquiring high-quality echocardiograms using standard ultrasound devices. This technology enhances the accessibility of ultrasound technology by enabling a wider range of healthcare professionals to perform these critical examinations. The company focuses on improving patient outcomes by enabling faster diagnoses, reducing wait times, and improving the efficiency of healthcare delivery. UltraSight's Go-to-Market strategy targets key areas; hospitals, clinics, and home healthcare settings, aiming to integrate their solution into existing workflows and improve patient care across various settings. The company emphasizes the importance of user-friendliness, ease of implementation, and a focus on patient safety and improved outcomes. With the company primed to make real impact, tune in so you can be informed and inspired.

This episode features Evan Ruff, CEO and Co-founder of Oxos Medical. Oxos Medical is developing innovative portable X-ray devices designed to revolutionize healthcare by bringing imaging to the point of need. Recognizing the limitations of traditional X-ray systems, which are often bulky, expensive, and require specialized infrastructure, Oxos Medical has created a compact and user-friendly device that can be easily used in various settings, from emergency departments and clinics to sports fields and even remote locations.Evan delves into the challenges of accessing traditional X-ray technology, including limited availability, high costs, and the need for specialized personnel. We discuss how Oxos Medical's portable X-ray device addresses these challenges by improving accessibility, enhancing workflow efficiency, and empowering clinicians with greater autonomy. The conversation also explores the potential of AI integration, such as AI-powered image analysis for improved diagnostic accuracy and streamlined workflows. With a strong sales pipeline in place, the OXOS team is primed to make an impact, tune in so you can be informed and inspired.

In this episode, Spencer Jones, Founder of XO Medtech, discusses the problem with innovation silos in medical technology and the commercialization process. Spencer highlights how innovators are often afraid to share information about what they are working on, and this can stifle progression. Additionally, there is a lack of access to open networks for comprehensive practical knowledge transfer related to commercialization.Spencer outlines how XO Medtech's platform offers a new online community approach for educating and connecting innovators, helping provide them with the resources needed to succeed. This includes a community forum, educational content, and a range of free templates. As well as aiding knowledge transfer, an additional platform, Medtech Vendors, will help improve the process of finding the right suppliers. With community and value-driven connections at the heart of all they do, this is definitely a conversation to keep you informed and inspired.Here are the key takeaways:Siloed nature of Medtech and Medtech innovation: Startup resources are often constrained by location and network which can hinder innovation.Limited access to specialized networking & knowledge training: Medtech innovators often have difficulty finding accessible resources and support they need to succeed.Importance of building a community: XO Medtech is building a community of Medtech innovators to help them connect with each other and share resources.Focus on actionable content: The platform provides innovators with access to practical tools and templates to help them advance their businesses.Standardization of processes: A new Medtech Vendors platform will help standardize the procurement process in the Medtech industry to improve efficiency.

In this episode, Swarna Shiv, CEO and founder of Unsmudgeable, delves into the challenges of smudged eyewear and how her company is revolutionizing lens technology. Unsmudgeable aims to eliminate the safety and productivity issues caused by smudged glasses, a huge problem that affects millions of people globally. Swarna shares insights into how the company started, the unique technology behind their coatings, and thee journey from idea to patent-pending innovation. Unsmudgeable's focus for 2025 is commercialization and they are actively working with lens manufacturers to apply this technology to various surfaces. Swarna explains their strategy for scaling up through equity crowdfunding and emphasizes the importance of sustainability in their product development. Tune in to be informed and inspired.

The episode discusses preventative care, specifically how virtual care can help people with chronic conditions manage their health and avoid hospitalization. David Dlesk, CEO and Co-Founder of Embrace Prevention Care, shares an overview of the challenges of preventative care in the current healthcare system and how Embrace helps patients with chronic conditions, like dementia, take action to improve their health.Embrace uses virtual consultations with nurse practitioners to provide ongoing support and coaching to patients. This helps patients make the lifestyle changes necessary to slow the progression of their chronic conditions. The Centers for Medicare & Medicaid (CMS) has created a new program, GUIDE, to specifically target dementia patients and caregivers. Embrace is one of the select organizations chosen to provide this program.The key takeaways from the podcast episode are:Preventative care is not currently well- incentivized in the healthcare system, but it is critical for managing chronic conditions.Virtual care can be an effective way to deliver preventative care.CMS has created a new program, GUIDE, to provide virtual preventative care to dementia patients and caregivers.Embrace is a company that is using virtual care to help people with chronic conditions manage their health and avoid hospitalization.

This episode features Ben Holmes, CEO and Co-founder of Nanochon, a medical device company focused on revolutionizing cartilage repair. The discussion highlights the significant challenges faced by patients with cartilage damage, including limited treatment options and the potential for further joint degeneration.Nanochon is developing a groundbreaking 3D-printed implant designed to mimic the natural structure and function of cartilage. This innovative device is designed to be minimally invasive and easily implanted, offering a potential solution for patients facing cartilage damage and potentially delaying or even preventing the need for knee replacement surgery.Ben shares insights into Nanochon's development progress, including upcoming human trials and their recent move to LaunchPort in Baltimore, a unique incubator space that provides access to state-of-the-art manufacturing facilities for medtech startups. With team expansion plans on the horizon, this story is fueled with insights, sure to leave you informed and inspired.

This episode discusses a huge unmet need in the medical device space: treatment for mixed urinary incontinence. Millions of patients, primarily women, suffer from this condition, and there is no effective treatment on the market. Current treatment options leave care gaps and patients resorting to over-the-counter products for symptom management.Juniper Biomedical is a company that is developing a new type of treatment for mixed urinary incontinence. They are developing a unique neuromodulation micro implant that can be implanted with a minimally invasive procedure to deliver a very precise therapy. This has the potential to solve the problems of mixed incontinence, eliminate issues with inaccurate diagnosis, and importantly, provide a solution that patients are more likely to accept.CEO and co-founder, David Constantine joins us to discuss their exciting progress, from extensive preclinical studies, to upcoming clinical trials. After a year of multiple highlights, including award winning on the stage of Medtech Innovator, the future looks bright for Juniper Biomedical. Their technology has the potential to make a real difference in the lives of millions of patients with pelvic health conditions, a story sure to leave you, informed and inspired.

This episode features Dave Rosa, CEO of NeuroOne, a company leading the way in innovative solutions for various neurological disorders. The discussion highlights the significant challenges faced by patients with epilepsy, particularly those whose condition is resistant to medication. Traditional treatment often involves multiple invasive surgeries, placing a significant physical and emotional burden on patients.NeuroOne has developed a groundbreaking technology that integrates both diagnostic and therapeutic functions into a single device. This innovative approach enables physicians to identify the source of seizures and then immediately proceed with ablation of the affected brain tissue within a single surgical procedure, minimizing patient discomfort and hospital stays. We explore the strategic partnership with Zimmer Biomet that has been pivotal for NeuroOne's successful market access, helping accelerate commercialization. With additional data insights, and future pharma collaboration opportunities, the future is truly bright for Dave and the team. NeuroOne is helping advance the movement towards personalized medicine, offering hope for improved patient outcomes, a story sure to leave you informed and inspired.

Novosound is a pioneering company in the field of ultrasound technology, with a mission to revolutionize the way we monitor vital signs. Traditional blood pressure monitoring methods, often involving bulky cuffs and infrequent measurements, can be inconvenient and provide limited insights. Novosound aims to address these limitations through their innovative, non-invasive, and continuous blood pressure monitoring solution.By leveraging advanced thin-film ultrasound technology, Novosound's sensors can be integrated into wearable devices, making it possible to track blood pressure in real-time. This continuous monitoring can provide valuable information to both patients and healthcare providers, enabling early detection of potential health issues and more effective management of conditions like hypertension.In this episode, we delve deeper into the technology behind Novosound's innovations. Dave Hughes, CEO and founder of Novosound, discusses the academic research foundation of the technology, along with the exciting potential for partners to leverage new capabilities with their wearable application. Dave details the company's strategy for a future where continuous, non-invasive monitoring becomes the norm, a story sure to leave you informed and inspired.

IntelVasc is a medical technology company focused on addressing the significant issue of peripheral arterial disease (PAD). This condition, often undiagnosed, can lead to serious complications like heart attacks and strokes. CEO & co-founder, Andrew Ortega-Verdaguer, joins this episode to discuss how he plans to lead the business from visionary prototype through to market as the team gears up for first FDA discussions early next year.The company's innovative solution involves a minimally invasive sensor, inserted subcutaneously near to the femoral artery. This sensor, paired with a portable scanner, will enable patients to monitor their vascular health at home. By collecting real-time data on blood flow, the technology can empower patients and clinicians to proactively identify potential issues and intervene early, reducing the risk of major complications.IntelVasc's technology has the potential to revolutionize the management of PAD. By providing a convenient and reliable method for monitoring vascular health, the company aims to improve patient outcomes, reduce healthcare costs, and enhance the overall quality of life for individuals with this condition. With additional AI and ML opportunities, this is an exciting medtech story sure to keep you informed and inspired.

Epilepsy is a neurological disorder affecting millions worldwide, significantly impacting the quality of life of both patients and their loved ones. Traditional management usually relies heavily on medication, which can have severe side effects. Despite the high prevalence of the condition, there is still a lack of objective data on seizure activity.EpiWatch CEO, Teresa Prego, joins this episode to discuss their wearable device designed to detect and alert for tonic-clonic seizures. By leveraging Apple Watch technology, EpiWatch provides real-time seizure detection and can alert caregivers, potentially reducing the risk of injury and improving response times. The device also collects valuable data on seizure patterns, enabling clinicians to make more informed treatment decisions.By partnering with clinicians, pharmaceutical companies, and device manufacturers, EpiWatch can integrate seamlessly with existing healthcare solutions, helping contribute to a broader ecosystem of epilepsy management. With FDA clearance planned for 2025, EpiWatch has the potential to revolutionize the way epilepsy is managed, improving the lives of patients and their families, a mission sure to leave you informed and inspired.

Bimal Maharjan, CEO & founder of GutSphere, joins the podcast to discuss the company's mission to empower patients with gastrointestinal (GI) issues. Bimal shares his personal journey with chronic GI conditions, highlighting the challenges patients face, such as embarrassment, lack of education, and difficulty navigating the healthcare system. GutSphere aims to address these challenges by providing a patient-centric platform that offers personalized education, symptom tracking, and community support. The platform leverages AI technology to provide tailored insights and a user-friendly experience. By combining technology with a deep understanding of patient needs, GutSphere has the potential to revolutionize GI care and improve the lives of millions of people.As GutSphere is currently in development, the team is focused on building a minimum viable product and gathering user feedback to refine the platform. Tune in so you can learn about Bimal's gut health mission and how to join the GutSphere community to help build a better solution for all patients to improve their gut health. This is a patient-centric story sure to leave you informed and inspired.

Novobeing is addressing a significant problem in healthcare: poor patient experience during hospital stays. Their solution involves using virtual reality technology to transport patients to calming environments, helping to reduce stress and anxiety. Beyond the direct benefits to patients, this also aims to improve HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) scores, as patient satisfaction increases.CEO and co-founder, Sid Desai, shares how their research studies are validating these benefits for hospitals systems, with exciting recent results from Massachusetts General Hospital providing further evidence. The company's initial focus is on patients undergoing stem cell transplant procedures, who often face prolonged hospital stays and isolation. Novobeing's VR technology offers a way to improve their mental well-being and overall experience. With several hospital systems already testing Novobeing's solution, Sid discusses the exciting opportunities, including the potential to reduce pharmacological interventions. As the healthcare industry embraces Medical VR, the vision of fully patient-centered care comes closer to reality. Novobeing is well placed to play a central role in this evolution, meaning this story is sure to leave you informed and inspired.

In this episode, we delve into the world of AI-powered healthcare with Shayan Mashatian, the founder of Pingoo.AI. You can learn how this innovative startup is applying AI to tackle a critical healthcare challenge: diabetic foot ulcers.Shayan highlights the alarming statistics surrounding diabetes and its complications, emphasizing the need for greatly improved patient education and engagement. Pingoo.AI's solution leverages AI to provide personalized education and support for patients, helping them understand their condition and manage it effectively.Shayan also shares how collaboration between healthcare providers, innovators, and patients, is leading to better AI integration and use of data. By leveraging technology and fostering a community-driven approach, the Pingoo.AI team is working towards a future where diabetes and its complications are better managed and ultimately prevented, a mission sure to leave you informed and inspired.

Novobeing is addressing a significant problem in healthcare: poor patient experience during hospital stays. Their solution involves using virtual reality technology to transport patients to calming environments, helping to reduce stress and anxiety. Beyond the direct benefits to patients, this also aims to improve HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) scores, as patient satisfaction increases.CEO and co-founder, Sid Desai, shares how their research studies are validating these benefits for hospitals systems, with exciting recent results from Massachusetts General Hospital providing further evidence. The company's initial focus is on patients undergoing stem cell transplant procedures, who often face prolonged hospital stays and isolation. Novobeing's VR technology offers a way to improve their mental well-being and overall experience.With several hospital systems already testing Novobeing's solution, Sid discusses the exciting opportunities, including the potential to reduce pharmacological interventions. As the healthcare industry embraces Medical VR, the vision of fully patient-centered care comes closer to reality. Novobeing is well placed to play a central role in this evolution, meaning this story is sure to leave you informed and inspired.

Prapela is a medical device company focused on improving newborn health. Their primary product is a specially designed mattress that uses gentle vibrations to regulate infant breathing, particularly for babies experiencing apnea of prematurity and neonatal opioid withdrawal syndrome.CEO & co-founder, John Konsin, joins this episode to share how many newborns, especially premature babies, experience breathing irregularities, including apnea and oxygen desaturation. Prapela's innovative mattress offers a non-invasive solution than can reduce the need for additional interventions while lowering costs for hospitals.Prapela's market potential is significant, as it addresses a common and serious issue affecting newborn infants. Building on decades of research and recent exciting clinical evidence, the Prapela journey is definitely one to track, be sure to tune in so you can be informed and inspired.

Millions of men suffer from premature (early) ejaculation, the most common sexual disorder in men younger than 40 years, with 30-70% of males in the United States affected to some degree at one time or another. This can be a major relationship issue for both partners and is often viewed as a challenging matter to discuss. Coupled with this, existing treatments like sprays, creams, and antidepressants have side effects or are found to be not very effective.Morari Medical's CEO and Founder, Jeff Bennett, joins this episode to share how they are developing a wearable patch that uses neurostimulation to delay ejaculation. The patch is placed on the perineum, the area between the scrotum and the penis, and users can control the settings through an app to find what works best for them.As Morari gears up for FDA approval and aims to be on the market in early 2025, Jeff discusses how he has transitioned from working at Boston Scientific to leading not just a startup, but a movement to make premature ejaculation no longer a taboo topic. From being spotlighted on Jimmy Kimmel, to winning numerous accolades, Jeff's story will be sure to leave you informed and inspired.

For episode 60, and one of the most popular recordings to date, we re-release the very first episode of the show where Rajit Kamal, currently VP & General Manager of Medtronic's Surgical Robotics division, joined us to talk about early-stage innovation.This is a must listen for any medtech entrepreneur as Rajit discusses how large medtech companies approach innovation and what they look for in early-stage startups. Rajit shares insights from his years of experience in the industry, developing winning teams, and how to overcome challenges bringing new solutions to patients. Be sure to tune in so you can be informed and inspired.

Jhonatan Bringas Dimitriades MD, CEO and co-founder of Lapsi Health, joins this episode to share insights into the company's newly launched product, Keikku—a revolutionary digital stethoscope designed to enhance the detection and monitoring of health conditions through advanced acoustic processing. Jhonatan discusses how Keikku is transforming traditional stethoscopes from simple listening devices into powerful data-driven tools that support medical diagnosis and patient monitoring. Initially targeting general healthcare professionals, Keikku is a part of Lapsi's broader vision to revolutionize health tracking. The stethoscope allows healthcare professionals to stream real-time sound clips and communicate securely, enabling faster and more accurate medical insights. Future software updates will incorporate AI-driven analysis for heart murmur detection and respiratory issues like wheezing, positioning Keikku at the forefront of smart medical devices. Throughout the discussion, Jhonatan emphasizes Lapsi Health's mission to make cutting-edge medtech more accessible and user-friendly for healthcare professionals and patients alike. With FDA clearance for Keikku already secured and additional approvals for AI features in the pipeline, the Lapsi team has a clear vision to position their hardware and software platform to help reshape how doctors and patients engage with medical technology. Listen in so you can be informed and inspired.

When you're talking to one the founding fathers of pulse field ablation, you know you're in for a real whirlwind of wisdom. Dr. Steven Mickelsen is a board-certified electrophysiologist who invented a pulsed electric field system and founded FARAPULSE in 2012. Ten years later, he is back at it again, with the founding of Field Medical Inc., as he looks to continue the crusade for superior cardiac ablation procedures.This discussion delves deep into the anatomical anomalies that ablation looks to tackle. Steven masterfully guides through the depths of the heart's chambers and the limitations of today's techniques. Through reverse engineering the problem, Field Medical is bringing new possibilities to tackling the underserved space of ventricular arrhythmia ablation.From the outset, Steven's knowledge makes this a truly insightful summary of all things pulsed field ablation related, with a good sprinkling of entrepreneurial sagacity. Nearly every innovative startup hones in on a true unmet need to get started, and Field Medical's blue ocean opportunity in VT makes this episode one that will be sure to leave you informed and inspired.

Kristin Nuckols, co-Founder & Chief Clinical Officer of Imago Rehab, joins this episode to discuss the challenges and opportunities in stroke rehabilitation. She highlights the increasing incidence of stroke and the devastating impact it can have on survivors and their families. She shares the challenges faced by healthcare providers in delivering effective post-stroke care, particularly in resource-limited settings.Kristin provides insights into her extensive experience as an Occupational Therapist and time in the Harvard Biodesign program that has allowed her to build a unique understanding of how high-quality rehabilitation for stroke survivors can improve their physical, cognitive, and emotional outcomes. Despite the numerous benefits of rehab, the growing number of patients mean new flexible solutions are essential to ensure the right care is available.Imago Rehab is developing innovative solutions to address these challenges, with a focus on making high-quality rehabilitation accessible to anyone recovering from a stroke. If you want to learn how soft robotics is being coupled with telemedicine to build a better future, then tune so you can be informed and inspired.

Millions of patients develop pressure injuries (bed sores) every year, often due to a lack of early detection. These wounds can lead to serious complications and even death. The current method of diagnosis relies on visual inspection by healthcare providers, which can be subjective and unreliable.Sanna Gaspard, CEO & Founder of Rubitection, joins this episode to discuss how she is developing a low-cost, easy-to-use medical device that uses optics to measure skin redness and inflammation, providing objective data for early detection of pressure injuries. The device is accompanied by a mobile app that allows clinicians to track changes in the wound, receive care recommendations, and capture images.Sanna shares insights around Rubitection's functional prototype that has shown positive results in initial human testing. Access is a key word throughout the episode, and this includes how the company is utilizing Wefunder to crowdfund the capital needed to advance the technology and ensure that the community can access investing in the venture.  Packed with impactful goals for patients, this story is sure to leave you informed and inspired.Be sure to join us on September 25-26 at MEDevice Boston where you can hear from other innovators leading the charge to help improve patient lives (use the code IMPACT to get your free expo pass and 20% conference ticket discount at the checkout).

Augie Shanahan, CEO of Piccolo Medical, joins this episode to discuss the challenges and opportunities in the field of central venous catheter placement. He highlights the limitations of current Peripherally inserted central catheter (PICC) technologies and the need for more accurate and reliable navigation methods.Piccolo Medical is developing innovative solutions to address these challenges, including their proprietary ionic dilution technology that provides real-time blood flow visualization. This technology has the potential to improve the accuracy and safety of catheter placement, especially in patients with arrhythmias.Augie shares insights into the company's journey, from its origins as a spin-out from the TheraNova incubator to its recent FDA clearance for the Easy Guide Connector. As an engineer turned CEO, Augie has plenty of great perspectives of the numerous challenges in successfully developing a novel medical, insights sure to leave you informed and inspired.Be sure to join us on September 25-26 at MEDevice Boston where you can hear from other innovators leading the charge to help improve patient lives (use the code IMPACT to get your free expo pass and 20% conference ticket discount at the checkout).

Chris Landon, CEO of Natus Neuro, joins us to discuss the challenges and opportunities in neurodiagnostics. Six months since being appointed, Chris shares a clear vision for Natus as he explains the need for improved access to diagnostic tools and the importance of data-driven insights for better patient care.Chris emphasizes the role of technology in addressing these challenges, including artificial intelligence and cloud-based solutions. A focus on patient-centric innovation is a recurring theme throughout the episode as Chris details their commitment to developing solutions that improve clinical workflows and patient outcomes.From winning principles in product development, to developing a global strategy with a new team, this conversation is a fantastic insight into how Chris is leading the Natus vision. If you want to learn about the latest neuro sensor trends, and how to execute a winning game plan to address these, then be sure to tune in so you can be informed and inspired.Be sure to join us on September 25-26 at MEDevice Boston where you can hear from other innovators leading the charge to help improve patient lives (use the code IMPACT to get your free expo pass and 20% conference ticket discount at the checkout).

Sydney Robinson, CEO & co-founder of Vessl Prosthetics, joins this episode to discuss how they are enhancing prosthetic technology. Her innovative company is developing an advanced prosthetic socket that can offer unparalleled comfort, mobility, and functionality for amputees.During the discussion, Sydney shares her personal journey and the critical medical innovation fellowship that led to the founding of Vessl Prosthetics. She discusses the challenges faced by amputees and the limitations of traditional prosthetic solutions. Vessl's mission is to address these shortfalls by providing truly accessible and customized solutions that improve the quality of life for users.We dive into the company's research and development efforts to reach these goals, including collaborating with Stevie Crawford as he trains for the 2026 Winter Paralympics. Sydney also shares insights into the latest advancements in prosthetic technology and the potential for future partnerships. As the company prepares for FDA approval, strap in and listen, so you can be informed and inspired.Be sure to join us on September 25-26 at MEDevice Boston where you can hear from other innovators leading the charge to help improve patient lives (use the code IMPACT to get your free expo pass and 20% conference ticket discount at the checkout).

SmartCardia is a medical technology company developing innovative solutions to improve cardiac care. The company's flagship product is a 7-lead ECG patch that collects vital signs and enables remote patient monitoring. This technology addresses the limitations of traditional ECG patches by providing more comprehensive data and facilitating real-time monitoring. Adam Kirchgessner, VP of Sales at SmartCardia, joins this episode to discuss the company's mission and technology. He highlights how they are helping provide accurate and accessible cardiac data for early detection and diagnosis of arrhythmias and other heart conditions. Adam also explains the significant value prop of their advanced platform that enables seamless data integration and analysis, empowering healthcare providers to make informed decisions. Beyond ECG monitoring, the company's goal is to become a comprehensive cardiac care solution, offering remote patient monitoring for conditions like heart failure and sleep apnea. Adam delves into what goes into building a winning sales team to achieve these ambitions, touching on his extended experience with other innovative technologies. Whatever your position in the medical technology space, this episode is packed with insights on delivering great innovation, a discussion sure to leave you informed and inspired. Be sure to join us on September 25-26 at MEDevice Boston where you can hear from other innovators leading the charge to help improve patient lives (use the code IMPACT to get your free expo pass and 20% conference ticket discount at the checkout).

For our 50th episode, we are joined by Mike Hugo, a patient advocate for Medtronic, who shares the story behind his battle with glioblastoma, a highly aggressive form of brain cancer. Mike's unique perspective as both a patient and industry insider offer valuable insights into the challenges and triumphs of navigating a complex medical condition. The discussion delves into Mike's journey, from initial diagnosis to experiences with a unique treatment pathway, and the impact of Novocure's incredible Optune technology that he wears every day. Mike's unwavering determination and positive outlook shine through as he explains his advocacy efforts, including supporting the Promising Pathway Act, to improve access to these types of advanced treatments for other patients. Beyond his personal story, Mike offers valuable insights into the medtech industry, sharing former experiences as a medtech sales professional and his passion for driving innovation in patient care. His firsthand knowledge of medical devices and advocacy work with his wife Vanessa, highlight the importance of collaboration between patients, healthcare providers, and industry leaders in advancing healthcare solutions. Listen in, and be prepared, to be truly, inspired and informed. Be sure to join us on September 25-26 at MEDevice Boston where you can hear from other innovators leading the charge to help improve patient lives (use the code IMPACT to get your 20% discount at the checkout).

After a needlestick injury, Dr. William Travis Lau conceived a safety suturing device to protect other healthcare workers from suffering a similar incident. Partnering with Joe Lane to help create what would become SafePath Medical, they started development of the first safety suturing device for catheter securement. Though Travis tragically passed away in 2019, his legacy endures through this life-saving innovation and his contributions to patient safety and blood management practices. SafePath's CEO Joe, joins this episode to share insights into the unique design challenges that have been overcome to realize Travis's vision, and create an ergonomic device that is capable of safe suturing for catheter securement and skin closure. With FDA clearance already in place for the intended use in placement of a silk suture in the skin and subcutaneous tissues, Joe discusses the multiple benefits that can now be made available to healthcare workers. This physician-backed solution is packed with engineering ingenuity and Joe shares how M2D2 is entwined in the backstory that helped the startup move from prototype to marketplace, leaving it primed to revamp the current standard of care. Under Joe's leadership, SafePath Medical is realizing not only Travis's vision, but a safer future for frontline healthcare workers. This is a true legacy story that is sure to leave you informed and inspired.

As a global leader in medical technologies, Stryker provides a wide range of innovative products to help improve patient and healthcare outcomes. With over 50,000 employees around the world working together to serve more than 150M patients annually, delivering a compliance driven culture is critical to the success of the business. Ultimately, whatever the size of your medtech organization, managing compliance risk means managing business risk. Dana McMahon, Chief Compliance Officer at Styker, joins this episode to share how she is collaborating with colleagues to ensure the organization has the mindset and tools needed to position multibillion-dollar projects for successful commercialization, profitable growth, and compliant operations across the value chain.  To cultivate a culture that moves past a tick box approach to compliance, Dana discusses how they have developed a structure that offers multiple touch points and brings elements of fun to engage employees. She highlights how their Code of Conduct refresh and launch campaign was awarded Stryker's Brand Implementation of the Year award at the Marketing Excellence Awards, a first for a functional team! With a thriving share price, Stryker's efforts around compliance are entwined with their growth over the past five years. If you're looking to learn from the best about what it takes to achieve this winning culture, and create real impact, then be sure to tune in so you can be informed and inspired.

Imricor Medical Systems is advancing the electrophysiology field by allowing physicians to perform cardiac ablation procedures in the growing number of interventional magnetic resonance (iCMR) suites found or being developed in leading hospitals. In this episode, we are joined by Imricor's Global Sales Leader, Greg Englehardt, to share the journey and their mission of bringing not just a set of innovative surgical tools to market, but also an entirely new operating environment! Where other large companies have tried and failed, Greg details how the company has navigated an array of technical challenges to make their solution successful. Between gaining Imricor's CE mark approval and navigating a product launch during the pandemic, combined with Greg's extensive experience with startups, this discussion is packed with insights. If you want to learn more about their upcoming US market development and how you could be part of a growing team then be sure to tune in so you can be informed and inspired.

Deep brain stimulation (DBS) is a neurosurgical procedure that treats neurological conditions by implanting electrodes into the brain to produce electrical impulses. These impulses can control abnormal brain activity and chemical imbalances that cause conditions like Parkinson's disease, essential tremor, and dystonia. Despite the benefits of DBS, less than 1% of the 25 million patients who are eligible to undergo the procedure opt-in due to the invasiveness of and risk associated with traditional open brain surgery. Nicky Driscoll, CTO of NeuroBionics, joins this episode to share how their team is on a mission to change the status quo through bioelectronic medicine. NeuroBionics is developing devices that seamlessly integrate with the human body and aim to offer DBS with a minimally-invasive approach. As well as learning about this exciting technology, Nicky shares insights into the journey from academic researcher to entrepreneur, and how they decided to focus on a challenging commercialization journey that could positively impact patient lives. As one of the top startups in the M2D2 accelerator program and recent winners the 2024 Vision Award with Medtech Innovator, the NeuroBionics story is definitely one to follow, and is sure to leave you informed and inspired.

Amplitude Vascular Systems (AVS) is a medical device company based in Boston, MA, focused on safely and effectively treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital and Cue Growth Partners to develop their innovative Pulse IVL System that has recently received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its pivotal trial.Angie Volk, VP of Business Development, and Sean Gilligan, COO of AVS, join this episode to share about their team's mission and how they are bringing this exciting technology to market. With Johnson & Johnson's $13.3B acquisition earlier this year of Shockwave Medical, the IVL space is showing that it is currently one of the hottest spaces in medtech. We discuss how AVS's Pulse IVL System is being designed to easily deliver therapy across complex calcified lesions and reduce overall procedural costs, making it hugely attractive to potential future acquirers.  As former Boston Scientific colleagues, Angie and Sean have extensive industry experience including unique insights of building a winning culture, and they are leveraging these learnings and their network to efficiently navigate their solution to patients across the globe. With two medtech veterans, this is a conversation brimming with helpful tips for any would-be entrepreneur that is sure to leave you informed and inspired.

The Future Health Index (FHI) survey conducted by Philips, a global leader in health technology, explores the challenges within healthcare systems and the innovative solutions being used to address them. From the survey findings, the recently released ninth annual report - 'Better Care for More People', demonstrates the pressures of staffing shortages and burnout on clinicians, and their ability to deliver timely, high-quality care to patients.  Jeff DiLullo, Chief Region Leader for Philips North America, joins this episode to discuss the findings and share how Philips is utilizing collaborative innovation to address the challenges. Jeff highlights the investments that healthcare leaders are making to help ease the burden on staff, such as automation and artificial intelligence, and those that are having an impact on increasing access and health equity such as virtual care.  Technology adoption is no longer a choice, but an imperative that leaders like Jeff are working with the community to bring solutions to where they are needed most. From AI to telehealth and virtual care, this conversation is a calling card to those who want to work together to foster innovation. Listen in for some wonderful takeaways from Jeff, and be sure to check out the Future Health Index 2024 Report so you can be informed and inspired.

Founded in 2017, XCath is a dynamic startup at the cutting edge of revolutionary medical robotics, nanorobotics and materials science. The company develops next-generation endovascular robotic systems and steerable guidewires to treat life-threatening conditions like cerebrovascular disorders.  With strategically located campuses in Houston, Texas – home to the world's largest medical center – and Pangyo, South Korea, often referred to as the Silicon Valley of Korea, XCath is committed to bringing its innovative solutions to patients around the world. CEO Eduardo Fonseca joins this episode to share how their family of engineers is making this a reality, with a value driven culture, and space-edge approach. After recently performing the world's first public telerobotic mechanical thrombectomy at Abu Dhabi Global Healthcare Week, it's clear that the XCath team is helping pave the way for widescale implementation of robotic surgical tools. Eduardo outlines how the team is building on this momentous landmark to tackle the eye-watering statistics associated with stroke, a conversation that is sure to leave you informed and inspired.

Founded in 2017, XCath is a dynamic startup at the cutting edge of revolutionary medical robotics, nanorobotics and materials science. The company develops next-generation endovascular robotic systems and steerable guidewires to treat life-threatening conditions like cerebrovascular disorders.  With strategically located campuses in Houston, Texas – home to the world's largest medical center – and Pangyo, South Korea, often referred to as the Silicon Valley of Korea, XCath is committed to bringing its innovative solutions to patients around the world. CEO Eduardo Fonseca joins this episode to share how their family of engineers is making this a reality, with a value driven culture, and space-edge approach. After recently performing the world's first public telerobotic mechanical thrombectomy at Abu Dhabi Global Healthcare Week, it's clear that the XCath team is helping pave the way for widescale implementation of robotic surgical tools. Eduardo outlines how the team is building on this momentous landmark to tackle the eye-watering statistics associated with stroke, a conversation that is sure to leave you informed and inspired.

Strokes are caused by blocked blood flow to the brain (ischemic stroke) or sudden bleeding in the brain (hemorrhagic stroke). About 87% of strokes are ischemic with the blockage in the brain usually caused by a piece of plaque or a blood clot. Like fingerprints, no two strokes are the same. Yet, conventional therapy options are limited and can compromise patient safety.​​ Rapid Medical's CEO and co-founder, Ronen Eckhouse joins this episode to share how they are bringing critical innovation to tackle ischemic strokes and enable physicians to respond in real-time to the brain's complex anatomy, helping tailor the procedure to every patient. Rapid Medical's uniquely designed stent is hard on the clot but soft on the vessel, this allows physicians to actively adapt to the fragile environment found in the brain. Ronen shares how the company has built value through strong partnerships, a growing patent portfolio, and ultimately helped bring enhanced outcomes for stroke patients in countries across the globe. With a long-term mission to solve big problems and some exciting new innovation on the horizon, Ronen's journey is one sure to leave you informed and inspired.

Vasectomy is a form of male birth control that cuts the supply of sperm to semen by cutting and sealing the tubes that carry sperm. The procedure has a low risk of problems and can usually be performed in an outpatient setting under local anesthesia. Despite contraceptive use worldwide increasing by 188 million users in the past 20 years, the number of vasectomy users fell by 27 million, a 61% decline, with almost all low-and-middle income countries reporting negligible vasectomy use. Female-to-male disparities in permanent method use have also widened further in the same period.Joining this episode, Signati Medical's CEO and Founder William ‘Billy' Prentice, shares how their company is dedicated to advancing men's health and changing the status quo. Signati plans to launch the first innovation in vasectomy in more than 20 years with a procedure that would be fast for physicians and comfortable for patients. Designed to take just minutes, this could be done right in the urologist's office and would offer easier recovery compared to some current techniques.From the get-go, Billy's drive and motivation to advance the accessibility of this procedure and reduce the burden of responsibility on women, is evident. From Wall Street trader turned entrepreneur, the story of Signati and Billy's journey is stacked with insights that are sure to leave you informed and inspired.

Hair loss affects more than 80 million Americans—approximately 50 million men and 30 million women. This market is large and complex, but most importantly, it represents a wide range of patients. For about 25% of American men, the balding process begins in their 20s and almost 85% will experience noticeable hair loss by their 50s. Women, on the other hand, can lose their hair for a variety of reasons ranging from postpartum hormones to menopause. Traditional transplant remedies can be invasive, leaving a linear scar, and incur significant downtime. In contrast, Venus hair restoration equipment provides the right tools for the physician to create a natural-looking hairline for their patients. Joseph ‘Joey' Brown, Global VP of Venus hair joins this episode to share how they are blending artificial intelligence with robotics to bring a new standard of treatment for patients.As someone who has suffered from hair loss himself, Joey shares honest insights into the mental anxiety faced, and why despite recent advance in hair transplant techniques, the robotic technology available via Venus's ARTAS system, offers a new elevated level of accuracy and precision not previously seen before in the procedure. With more than 25 years of extensive industry knowledge, combined with Joey's passion for helping other patients tackle their hair loss condition, this conversation is sure to leave you informed and inspired.

While the U.S. leads in many areas of healthcare innovation, it also lags behind much of the industrialized world in providing care for some of its most vulnerable populations. When it comes to maternal health, March of Dimes reports that a woman dies every 12 hours from pregnancy-related causes, deaths that show huge disparities and could be prevented. As an international leader in healthcare innovation, Philips is investing billions of dollars every year to advance R&D and help tackle health disparities. Jennifer Law, Philips' recently appointed Maternal Health Leader, joins this episode to share how they are partnering with customers to increase productivity and deliver better care for more mothers across the world.Jennifer shares insights into some of the technology that is shaping improved outcomes, helping to reach people in new places, and with enhanced intelligence. From AI to tele-health solutions, the underpinning factor is an inclusive approach that has a personal touch. Tune in to learn more about how Jennifer is helping guide Philips' mission in maternal health, a story packed with passion that is sure to leave you informed and inspired.

In this enlightening episode, CEO & co-founder Melody Roberts delves into the often-overlooked topic of stress urinary incontinence (SUI) and its impact on women's lives. SUI, a condition where physical movement or activity causes involuntary leakage of urine, affects millions of women, impacting their confidence and quality of life. Melody breaks down the causes, from childbirth to menopause, and the daily challenges women face, including the stigma and emotional toll associated with the condition.Melody introduces the innovative work being done at Liv Labs, a company dedicated to empowering women through education and novel solutions. She highlights Liv Labs' comprehensive online education platform, designed to provide women with the knowledge and resources they need to understand and manage SUI. Moreover, you can learn about Liv Labs' development of a cutting-edge pessary solution—a non-invasive device that offers a discreet and effective way to manage symptoms, allowing women to regain control and live their lives without interruption.Join Melody as she shines a light on SUI and shares how Liv Labs is pioneering change, providing hope, and improving the lives of countless women around the world. From their dynamic design duo roots to a mission centered around community, this is a conversation sure to leave you informed and inspired.

Large numbers of people are affected by infertility in their lifetime. According to a new report published today by the World Health Organization, around 17.5% of the adult population – roughly 1 in 6 worldwide – experience infertility, showing the urgent need to increase access to affordable, high-quality fertility care for those in need.The new estimates show limited variation in the prevalence of infertility between regions. The rates are comparable for high-, middle- and low-income countries, indicating that this is a major health challenge globally. Lifetime prevalence was 17.8% in high-income countries and 16.5% in low- and middle-income countries.Joining this episode to share their mission to solve some of the problems couples are facing, is the dynamic duo of Andreia Trigo (CEO) and husband Frank Khan Sullivan (CTO) of Enhanced Fertility. Their platform is bringing a new level of data-driven accessibility to patients from the comfort of their homes. Andreia's shares how current inadequate systems impacted her own fertility journey, an emotional story that sets the stage for the collaborative program they are providing to deliver better outcomes for couples across the globe.Founders' stories are often intertwined with personal knowledge of the problem they are looking to solve. From the get-go learning about Andreia's own experiences, this discussion offers a range of insights into the trials and tribulations that couples are facing through their fertility journeys. Frank shares how their North Star is referred to as Net Baby Score, a measured commitment to help millions of people procreate their families, an incredible mission that is sure to leave you informed and inspired.

Breast cancer is the most commonly occurring cancer in women and the most common cancer overall. Treatment often starts with a surgery known as a lumpectomy to remove the cancer, but in a high % of cases, patients may undergo multiple re-excisions after their procedure in an attempt to obtain clear margins and avoid mastectomy.In this episode, CEO of Dilon Technologies, George Makhoul, shares how they are helping to significantly reduce the need for re-excision with the use of their MarginProbe. A lumpectomy is a challenging surgical procedure, complicated by two obvious yet conflicting priorities: excise as much tissue as necessary to remove the cancer from the breast, remove as little tissue as possible to achieve the best cosmetic result.The MarginProbe System is designed to give today's surgeons a significant new advantage in margin assessment. In a procedure of roughly five minutes, MarginProbe provides real-time, detailed information to help a surgeon decide whether additional tissue should be taken, or whether to complete the lumpectomy procedure and close the incision.George's background in marketing gives him a strong edge in the art of communication with stakeholders which shines through as he details the technology's journey over the past four years. His consummate professionalism in articulating a clear approach and vision, has helped position Dilon as a leader in its field, backed up by some game-changing innovation that can significantly improve the outcomes for patients. With an inspiring mission for creating impact across the globe for women, this discussion will truly leave you informed and inspired.

The rigid, plastic T-shaped intrauterine device (IUD) has been available for over 40 years, with little to no innovation. Insertion is painful and involves numerous painful steps, and removal requires bothersome dangling strings, which are a nuisance for women and their partners. Most importantly, the pain associated with insertion and removal is widely known, leading to a nearly universal fear, particularly among younger women, of selecting an IUD. This ‘fear factor' is a significant barrier that prevents women from adopting one of the most effective forms of contraception. 3Daughters' goal is to eliminate this barrier to adoption and radically transform the IUD experience for both practitioners and patients.Mary Beth Cicero, CEO and co-founder of 3Daugthers, joins this episode to share how their innovative design forms a small frameless magnetic IUD that self-assembles in the uterus and conforms to a women's body – with no strings attached. Through technological and scientific advancements, 3Daughters is addressing the pain and resulting ‘fear factor' of IUD insertion.Alongside experienced co-founder Shelley Amster, Mary Beth discusses how in just two years the company has already made significant progress to translate their novel approach. With a comprehensive system and high-performance team, there is a belief within that this could be the first billion-dollar women's health product. Big problems require big vision thinking, and it's clear through this conversation that this is a team brimming with the passion and perseverance to realize their goals. As a seasoned consultant and marketer, Mary Beth offers some welcome insights as to what it takes to build a solution when those around you might not share the same optimism. #IUD has been trending for the wrong reasons and 3Daughters is on a mission to change the status quo. If you're ready to be informed and inspired, then listen in.